RxDoctor Payments Data

Marimer Rivera, MD

Family Medicine · McAllen, TXNPI 1255651071

Payments from drug & device makers

$1,748in general payments, 2019–2025

Across 70 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$607
  • AstraZeneca$318
  • Novo Nordisk$197
  • AbbVie$182
  • Genentech USA, Inc.$93
  • Takeda Pharmaceuticals U.S.A., Inc.$81
  • plus $272 from 8 others

What the payments were for

  • Food & beverage$1,748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,748 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$894,668
Medicare patients
400
Services billed
8,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$57,067
EliquisApixaban140$47,440
JardianceEmpagliflozin86$38,668
MounjaroTirzepatide27$32,388
JanuviaSitagliptin Phosphate57$24,137
XareltoRivaroxaban39$23,183
TrulicityDulaglutide11$18,868
FarxigaDapagliflozin Propanediol32$17,784
Janumet XrSitagliptin Phos/Metformin Hcl14$16,483
LinzessLinaclotide24$15,617
EntrestoSacubitril/Valsartan25$8,867
Memantine Hcl371$8,263
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,370
Tresiba Flextouch U-200Insulin Degludec19$6,253
Glucagon Emergency KitGlucagon16$5,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$197$57,06759 claims
AstraZenecaFarxiga$318$17,78432 claims
AbbVieLinzess$182$15,61724 claims
Astellas Pharma US IncMyrbetriq$21$2,47812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →